-
Forest Laboratories Holdings Ltd. et al v. Apotex Corp. et al DC CAFC
- 1:13-cv-01602
- D. Del.
- Judge: Sue L. Robinson
- Filed: 09/23/2013
- Closed: 07/11/2016
- Latest Docket Entry: 12/18/2017
- PACER
3
Plaintiffs
19
Defendants
1
Accused
Product
3
Patents-in-Suit
1,023
Days in
Litigation
-
Forest Laboratories Holdings Ltd. et al v. Apotex Corp. et al DC CAFC
- 1:13-cv-01602
- D. Del.
- Judge: Sue L. Robinson
- Filed: 09/23/2013
- Closed: 07/11/2016
- Latest Docket Entry: 12/18/2017
- PACER
Cause of Action
Infringement
Market Sector
Biotech and Pharma
Court
Assigned Judge
Outcome Summary
- Patent Information
-
Validity & Enforceability
-
Infringement
Mylan Incorporated
- 3 Details
| Accused Product | Patent # | Claim # | Outcome |
|---|---|---|---|
| 100 mg dosage25 mg50 mgGeneric 12.5 mg, 25 mg, 50 mg, 100 mg Milnacipran hydrochloride tabletsMilnacipran Hydrochloride Tablets 12.5 mgMilnacipran hydrochloride tablets in 100 mg dosage strengthsMilnacipran hydrochloride tablets in 12.5 mg dosage strengthsMilnacipran hydrochloride tablets in 25 mg dosage strengthsMilnacipran hydrochloride tablets in 50 mg dosage strengths | US 6,602,911 B2 | All Asserted Claims |
Infringement
Entry 295Entry 288 Entry 286 |
| 100 mg dosage25 mg50 mgGeneric 12.5 mg, 25 mg, 50 mg, 100 mg Milnacipran hydrochloride tabletsMilnacipran Hydrochloride Tablets 12.5 mgMilnacipran hydrochloride tablets in 100 mg dosage strengthsMilnacipran hydrochloride tablets in 12.5 mg dosage strengthsMilnacipran hydrochloride tablets in 25 mg dosage strengthsMilnacipran hydrochloride tablets in 50 mg dosage strengths | US 7,888,342 B2 | All Asserted Claims |
Infringement
Entry 295Entry 288 Entry 286 |
| 100 mg dosage25 mg50 mgGeneric 12.5 mg, 25 mg, 50 mg, 100 mg Milnacipran hydrochloride tabletsMilnacipran Hydrochloride Tablets 12.5 mgMilnacipran hydrochloride tablets in 100 mg dosage strengthsMilnacipran hydrochloride tablets in 12.5 mg dosage strengthsMilnacipran hydrochloride tablets in 25 mg dosage strengthsMilnacipran hydrochloride tablets in 50 mg dosage strengths | US 7,994,220 B2 | All Asserted Claims |
Infringement
Entry 295Entry 288 Entry 286 |
Mylan Pharmaceuticals Incorporated
- 3 Details
| Accused Product | Patent # | Claim # | Outcome |
|---|---|---|---|
| 100 mg dosage25 mg50 mgGeneric 12.5 mg, 25 mg, 50 mg, 100 mg Milnacipran hydrochloride tabletsMilnacipran Hydrochloride Tablets 12.5 mgMilnacipran hydrochloride tablets in 100 mg dosage strengthsMilnacipran hydrochloride tablets in 12.5 mg dosage strengthsMilnacipran hydrochloride tablets in 25 mg dosage strengthsMilnacipran hydrochloride tablets in 50 mg dosage strengths | US 6,602,911 B2 | All Asserted Claims |
Infringement
Entry 295Entry 288 Entry 286 |
| 100 mg dosage25 mg50 mgGeneric 12.5 mg, 25 mg, 50 mg, 100 mg Milnacipran hydrochloride tabletsMilnacipran Hydrochloride Tablets 12.5 mgMilnacipran hydrochloride tablets in 100 mg dosage strengthsMilnacipran hydrochloride tablets in 12.5 mg dosage strengthsMilnacipran hydrochloride tablets in 25 mg dosage strengthsMilnacipran hydrochloride tablets in 50 mg dosage strengths | US 7,888,342 B2 | All Asserted Claims |
Infringement
Entry 295Entry 288 Entry 286 |
| 100 mg dosage25 mg50 mgGeneric 12.5 mg, 25 mg, 50 mg, 100 mg Milnacipran hydrochloride tabletsMilnacipran Hydrochloride Tablets 12.5 mgMilnacipran hydrochloride tablets in 100 mg dosage strengthsMilnacipran hydrochloride tablets in 12.5 mg dosage strengthsMilnacipran hydrochloride tablets in 25 mg dosage strengthsMilnacipran hydrochloride tablets in 50 mg dosage strengths | US 7,994,220 B2 | All Asserted Claims |
Infringement
Entry 295Entry 288 Entry 286 |
